Qinghua Wang
6PUBLICATIONS
1CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Dec 11, 2022
Identification and Validation of RELN Mutation as a Response Indicator for Immune Checkpoint Inhibitor Therapy in Melanoma and Non-Small Cell Lung Cancer.Zhenpeng Li, Xin Wang, Yi Yang
|Nov 26, 2022
Fatty Acid Synthase Mutations Predict Favorable Immune Checkpoint Inhibitor Outcome and Response in Melanoma and Non-Small Cell Lung Cancer Patients.Qinghua Wang, Na Tian, Wenjing Zhang
|Jul 27, 2022
HSPG2 Mutation Association with Immune Checkpoint Inhibitor Outcome in Melanoma and Non-Small Cell Lung Cancer.Wenjing Zhang, Zhijuan Lin, Fuyan Shi
|Jun 23, 2022
Favorable immune checkpoint inhibitor outcome of patients with melanoma and NSCLC harboring FAT1 mutations.Wenjing Zhang, Yunfeng Tang, Yuxian Guo
|Dec 30, 2021
An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Wenjing Zhang, Yuting Li, Juncheng Lyu
|Dec 04, 2021
Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.Wenjing Zhang, Fuyan Shi, Yujia Kong
Pageof 1
